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Abstract 
ABSTRACT 
Introduction 
Kidney transplantation confers both survival and quality of life advantages over 
dialysis for most people with end-stage kidney disease (ESKD). The mortality rate 
on dialysis is 10-15% per year, compared with 2-4% per year post-transplantation.  
Short-term graft survival is related to control of the acute rejection process, 
requiring on-going immunosuppression. Most current immunosuppressive 
algorithms include one of the calcineurin inhibitors (CNI: cyclosporin or 
tacrolimus), an anti-metabolite (azathioprine or mycophenolate) and 
corticosteroids, with or without antibody induction agents (Ab) given briefly peri-
transplantation. Despite this approach, between 15-35% of recipients undergo 
treatment for an episode of acute rejection (AR) within one year of transplantation.  
Transplantation is not without risk, and relative mortality rates for kidney recipients 
after the first post-transplant year remain 4-6 times that of the general population. 
Longer-term transplant and recipient survival are related to control of chronic 
allograft nephropathy (rooted in the interplay of AR, non-immunological factors, 
and the chronic nephrotoxicity of CNI) and limitation of the complications of 
chronic ESKD and long-term immunosuppression: cardiovascular disease, cancer 
and infection, which are responsible for 22%, 39% and 21% of deaths 
respectively. 
This thesis is presented as published works on the theme of immunosuppression 
and cancer after kidney transplantation. The work presented in the first chapters of 
this thesis has striven to identify, evaluate, synthesise and distil the entirety of 
evidence available of new and established immunosuppressive drug agents 
through systematic review of randomised trial data, with particular emphasis on 
quantifying harms of treatment. The final chapters use inception cohort data from 
the Australian and New Zealand Dialysis and Transplant Registry (ANZDATA), 
which is first validated then used to explore the risk of cancer in more detail than 
was possible from trial data alone.  
Interleukin 2 receptor antagonists  
Interleukin-2 receptor antagonists (IL2Ra, commercially available as basiliximab 
and daclizumab) are humanised or chimeric IgG monoclonal antibodies to the 
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alpha subunit of the IL2 receptor present only on activated T lymphocytes, and the 
rationale for their use has been as induction agents peri-transplantation. 
Introduced in the mid-1990s, IL2Ra use has increased globally, and by 2003 38% 
of new kidney transplant recipients in the United States and 25% in Australasia 
received an IL2Ra. This study aimed to systematically identify and synthesise the 
evidence of effects of IL2Ra as an addition to standard therapy, or as an 
alternative to other induction agents. 
We identified 117 reports from 38 randomised trials involving 4893 participants. 
Where IL2Ra were compared with placebo (17 trials; 2786 patients), graft loss was 
not different at one (Relative Risk -RR 0.84; 0.64 to 1.10) or 3 years (RR 1.08; 
0.71 to1.64). AR was reduced at 6 months (RR 0.66; 0.59 to 0.74) and at 1 year 
(RR 0.66; 0.59 to 0.74) but cytomegalovirus (CMV) disease (RR 0.82; CI 0.65 to 
1.03) and malignancy (RR 0.67; 0.33 to1.36) were not different. Where IL2Ra 
were compared with other antibody therapy no significant differences in treatment 
effects were demonstrated, but IL2Ra had significantly fewer side effects. 
Given a 40% risk of rejection, 7 patients would need treatment with IL2Ra in 
addition to standard therapy, to prevent 1 patient having rejection, with no definite 
improvement in graft or patient survival. There was no apparent difference 
between basiliximab and daclizumab. 
Tacrolimus versus cyclosporin for primary immunosuppression  
There are pronounced global differences in CNI use; 63% of new kidney transplant 
recipients in the USA but only 22% in Australia receive tacrolimus as part of the 
initial immunosuppressive regimen. The side effects of CNI differ: tacrolimus is 
associated more with diabetes and neurotoxicity, but less with hypertension and 
dyslipidaemia than cyclosporin, with uncertainty about equivalence of 
nephrotoxicity or how these relate to patient and graft survival, or impact on patient 
compliance and quality of life. This study aimed to systematically review and 
synthesise the positive and negative effects of tacrolimus and cyclosporin as initial 
therapy for renal transplant recipients. 
We identified 123 reports from 30 randomised trials involving 4102 participants. At 
6 months graft loss was reduced in tacrolimus-treated recipients (RR 0·56; 0·36 to 
0·86), and this effect persisted for 3 years. The relative reduction in graft loss with 
tacrolimus diminished with higher levels of tacrolimus (P=0.04), but did not vary 
 vi
Abstract 
with cyclosporin formulation (P=0.97) or cyclosporin level (P=0.38).  At 1 year, 
tacrolimus patients suffered less AR (RR 0·69; 0·60 to 0·79), and less steroid-
resistant AR (RR 0·49; 0·37 to 0·64), but more insulin-requiring diabetes (RR 1·86; 
1·11 to 3·09), tremor, headache, diarrhoea, dyspepsia and vomiting. The relative 
excess in diabetes increased with higher levels of tacrolimus (P=0.003). 
Cyclosporin-treated recipients experienced significantly more constipation and 
cosmetic side-effects. We demonstrated no differences in infection or malignancy.  
Treating 100 recipients with tacrolimus instead of cyclosporin for the 1st year post-
transplantation avoids 12 suffering acute rejection and 2 losing their graft but 
causes an extra 5 to become insulin dependent diabetics, thus optimal drug choice 
may vary among patients.  
Target of rapamycin inhibitors for primary immunosuppression  
Target of rapamycin inhibitors (TOR-I) are among the newest immunosuppressive 
agents and have a novel mode of action but uncertain clinical role. Sirolimus is a 
macrocyclic lactone antibiotic and everolimus is a derivative of sirolimus. Both 
prevent DNA synthesis resulting in arrest of the cell cycle. Animal models 
suggested TOR-I would provide synergistic immunosuppression when combined 
with CNI, but early clinical studies demonstrated synergistic nephrotoxicity. Since 
then diverse trials have explored strategies that avoid this interaction and 
investigated other potential benefits. The aim of this study was to systematically 
identify and synthesise available evidence of sirolimus and everolimus when used 
in initial immunosuppressive regimens for kidney recipients.  
We identified 142 reports from 33 randomised trials involving 7114 participants, 
with TOR-I evaluated in four different primary immunosuppressive algorithms: as 
replacement for CNI, as replacement for antimetabolites, in combination with CNI 
at low and high dose, and with variable dose of CNI. When TOR-I replaced CNI (8 
trials, 750 participants), there was no difference in AR (RR 1.03; 0.74 to 1.44), but 
creatinine was lower (WMD -18.31 umol/l; -30.96 to -5.67), and bone marrow more 
suppressed (leucopoenia RR 2.02; 1.12 to 3.66, thrombocytopenia RR 6.97; 2.97 
to 16.36, anaemia RR 1.67; 1.27 to 2.20). When TOR-I replaced antimetabolites 
(11 trials, 3966 participants), AR and CMV were reduced (RR 0.84; 0.71 to 0.99 
and RR 0.49; 0.37 to 0.65) but hypercholesterolaemia was increased (RR 1.65; 
1.32 to 2.06). When low was compared to high-dose TOR-I, with equal CNI dose 
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(10 trials, 3175 participants), AR was increased (RR 1.23; 1.06 to 1.43) but GFR 
higher (WMD 4.27 ml/min; 1.12 to 7.41). When low-dose TOR-I and standard-dose 
CNI were compared to higher-dose TOR-I and reduced CNI AR was reduced (RR 
0.67; 0.52 to 0.88), but GFR also reduced (WMD -9.46 ml/min; -12.16 to -6.76). 
There was no significant difference in mortality, graft loss or malignancy risk 
demonstrated for TOR-I in any comparison.  
Generally surrogate endpoints for graft survival favoured TOR-I (lower risk of 
acute rejection and higher GFR) and surrogate endpoints for patient outcomes 
were worsened by TOR-I (bone marrow suppression, lipid disturbance). Long-term 
hard-endpoint data from methodologically robust randomised trials are still 
needed. 
Monoclonal and polyclonal antibody therapy for treating acute rejection  
Strategies for treating AR include pulsed steroids, an antibody (Ab) preparation, 
the alteration of background immunosuppression, or combinations of these 
options. In 2002, in the USA 61.4% of patients with AR received steroids, 20.4% 
received Ab and 18.2% received both. The Ab available for AR are not new: horse 
and rabbit derived polyclonal antibodies (ATG and ALG) have been used for 35 
years, and a mouse monoclonal antibody (muromonab-CD3) became available in 
the late 1980s. These preparations remove the functional T-cell population from 
circulation, producing powerful saturation immunosuppression which is useful for 
AR but which may be complicated by immediate toxicity and higher rates of 
infection and malignancy. The aim of this study was to systematically evaluate and 
synthesise all evidence available to clinicians for treating AR in kidney recipients. 
We identified 49 reports from 21 randomised trials involving 1394 participants. 
Outcome measures were inconsistent and incompletely defined across trials. 
Fourteen trials (965 patients) compared therapies for 1st AR episodes (8 Ab 
versus steroid, 2 Ab versus another Ab, 4 other comparisons). In treating first 
rejection, Ab was better than steroid in reversing AR (RR 0.57; CI 0.38 to 0.87) 
and preventing graft loss (RR 0.74; CI 0.58 to 0.95) but there was no difference in 
preventing subsequent rejection (RR 0.67; CI 0.43 to 1.04) or death (RR 1.16; CI 
0.57 to 2.33) at 1 year. Seven trials (422 patients) investigated Ab treatment of 
steroid-resistant rejection (4 Ab vs another Ab, 1 different doses Ab, 1 different 
formulation Ab, 2 other comparisons). There was no benefit of muromonab-CD3 
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over ATG or ALG in reversing rejection (RR 1.32; CI 0.33 to 5.28), preventing 
subsequent rejection (RR 0.99; CI 0.61 to 1.59), graft loss (RR 1.80; CI 0.29 to 
11.23) or death (RR 0.39; CI 0.09 to 1.65).  
Given the clinical problem caused by AR, comparable data are sparse, and 
clinically important differences in outcomes between widely used interventions 
have not been excluded. Standardised reproducible outcome criteria are needed. 
Validity of cancer data in an end stage kidney disease registry  
Registries vary in whether the data they collect are given voluntarily or as a 
requirement of law, the completeness of population coverage, the breadth of data 
collected and whether data are assembled directly or indirectly through linkage to 
other databases. Data quality is crucial but difficult to measure objectively. Formal 
audit of ANZDATA cancer records has not previously taken place. The aim of this 
study was to assess agreement of records of incident cancer diagnoses held in 
ANZDATA (voluntary reporting system) with those reported under statute to the 
New South Wales (NSW) state Central Cancer Registry (CCR), to explore the 
strengths and weaknesses of both reporting systems, and to measure the impact 
of any disagreement on results of cancer analyses. 
From 1980-2001, 9453 residents received dialysis or transplantation in NSW. 
Records from ANZDATA registrants were linked to CCR using probabilistic 
matching and agreement between registries for patients with 1 or more cancers, 
all cancers and site-specific cancer was estimated using the kappa-statistic (κ). 
ANZDATA recorded 867 cancers in 779 (8.2%) registrants; CCR 867 cancers in 
788 (8.3%), with κ =0.76. ANZDATA had sensitivity 77.3% (CI 74.2 to 80.2), 
specificity 98.1% (CI 97.7 to 98.3) if CCR records were regarded as the reference 
standard. Agreement was similar for diagnoses whilst receiving dialysis (κ =0.78) 
or after transplantation (κ =0.79), but varied by cancer type. Melanoma (κ =0.61) 
and myeloma (κ =0.47) were less good; lymphoma (κ =0.80), leukaemia (κ =0.86) 
and breast cancer (κ =0.85) were very good. Artefact accounted for 20.8% non-
concordance but error and misclassification did occur in both registries. Cancer 
risk did not differ in any important way whether estimated using ANZDATA or CCR 
records. 
Quality of cancer records in ANZDATA are high, differences largely explicable, 
and seem unlikely to alter results of analyses. 
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Risk of cancer after kidney transplantation 
Existing data on the magnitude of excess risk of cancer across different kidney 
recipient groups are sparse. Quantifying an individual transplant candidate’s 
cancer risk informs both pre-transplant counselling, treatment decisions and has 
implications for monitoring, screening and follow-up after transplantation. The aims 
of this study were firstly to establish the risk of cancer in the post-transplant 
population compared to that experienced by the general population, and secondly 
to quantify how excess risk varied within the transplanted population, seeking to 
establish meaningful absolute risk estimates for post-transplant cancer based on 
unalterable recipient characteristics known a priori at the time of transplantation.  
15,183 residents of Australia and New Zealand had a transplant between 1963 
and 2004, and were followed for a median of 7.2 years (130,186 person-years), 
with 1642 (10.8%) developing cancer. Overall, kidney recipients had 3 times the 
cancer risk, with risk inversely related to age (Standardised Incidence Ratio of 15 
to 30 in children reducing to 2 in people > 65 years). Female recipients aged 25 -
29 had rates of cancer (779.2/100,000) equivalent to women aged 55 - 59 from the 
general population. The risk pattern of lymphoma, colorectal and breast cancer 
was similar to the overall age trend, melanoma showed less variability across ages 
and prostate cancer showed no risk increase. Within the transplanted population 
cancer risk was affected by age differently for each sex (P=0.007), and was 
elevated for recipients with prior non-skin malignancy (Hazard Ratio: HR 1.40; 
1.03 to 1.89), of white race (HR 1.36; 1.12 to 1.89), but reduced for those with 
diabetic ESKD (HR 0.67; 0.50 to 0.89) 
Rates of cancer in kidney recipients were similar to non-transplanted people 20 -
30 years older, but risk differed across patient groups. Men aged 45 - 54 at 
transplantation with graft function at 10 years had a risk of cancer that varied from 
1 in 13 (non-white, diabetic ESKD, no prior cancer) to 1 in 5 (white, prior cancer, 
ESKD from other causes).  
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